totalwealthresearch.com Open in urlscan Pro
18.233.27.104  Public Scan

Form analysis
4 forms found in the DOM

GET https://totalwealthresearch.com/

<form role="search" method="get" id="searchform" class="searchform" action="https://totalwealthresearch.com/">
  <input class="w-100" type="text" name="s" id="s" aria-label="Search" placeholder="Search">
</form>

GET https://totalwealthresearch.com

<form role="search" method="get" id="searchform" class="searchform" action="https://totalwealthresearch.com">
  <input type="text" class="search" name="s" id="s" aria-label="Search" placeholder="Search">
</form>

POST https://signup.manwardpress.com/Content/SaveFreeSignups

<form id="LeadGen" class="lg_form" method="post" action="https://signup.manwardpress.com/Content/SaveFreeSignups">
  <input class="mvcode" name="MultivariateId" type="hidden" value="X3204320">
  <input name="NotSaveSignup" type="hidden" value="False">
  <input class="coreg" type="hidden" name="CoRegs" value="350727, 323741, 253444">
  <input class="email" name="email" maxlength="255" type="text" placeholder="Enter Your Email" id="email" value="" required="">
  <input class="leadSubmit" name="submit" type="submit" value="SIGN ME UP!">
</form>

POST https://signup.manwardpress.com/Content/SaveFreeSignups

<form id="LeadGen" class="lg_form" method="post" action="https://signup.manwardpress.com/Content/SaveFreeSignups">
  <input class="mvcode" name="MultivariateId" type="hidden" value="X3204322">
  <input name="NotSaveSignup" type="hidden" value="False">
  <input class="coreg" type="hidden" name="CoRegs" value="350727, 323741, 253444">
  <input class="email" name="email" maxlength="255" type="text" placeholder="Enter Your Email" id="email" value="" required="">
  <input class="leadSubmit" name="submit" type="submit" value="SIGN ME UP!">
</form>

Text Content

 * Stocks
 * Gold
 * Crypto
 * Manward Trading Academy
   
   
   MANWARD TRADING ACADEMY
   
   Learn to trade like a pro... for free! This premium archive of resources,
   videos and how-tos is available to all  Manward Financial Digest
    subscribers.
   
   Learn More
 * About Us
   * Our Story
   * Our Investment Philosophy
   * Our Contributors
   * Media
 * 




SIGN UP TO RECEIVE THE BEST INVESTING TIPS AND TRICKS IN YOUR INBOX DAILY FROM
OUR FREE E-LETTER TOTAL WEALTH.



By submitting your email address, you will receive a free subscription to the
Total Wealth e-letter, and offers from us and our affiliates that we think might
interest you. You can unsubscribe at any time. Privacy Policy.


DEALMAKER’S DIARY: THIS BIOTECH IS FIGHTING A SILENT KILLER

ALPESH PATEL|JUNE 20, 2024

Chronic and life-threatening diseases are on the rise…

But one company stands tall in the fight against a silent killer: pulmonary
arterial hypertension.

It’s a $12 billion biotech with a track record of impressive run-ups.

And when I put it through my proprietary Value-Growth-Income algorithm… the
results are stunning.

A score of 9 out of 10. A forecast P/E ratio of just 11.5. And a cash return on
capital invested of 12%.

In a sector known for volatility, this stock is a rare beacon of stability.

Plus… it has a potential upside of 60% based on its discount cash flow
valuation.

Don’t miss out on the potential of this biotech gem.

Get all the details on the company – including the ticker – in my latest video.

Click on the image below to check it out.



Click for sound





2:33












TRANSCRIPT

It’s Stock of the Week time. Now, from where I am, it’s Father’s Day, so you
might hear my son in the background. He’s done some wonderful diagrams there and
left half the cupboards open.



The grand reveal… United Therapeutics (UTHR).

So what is it about the company? Why is it in the Dealmaker’s Diary?

Well, it’s had some good run-ups. It’s a biotech company that engages in the
development and commercialization of unique products to address unmet medical
needs… particularly those that are chronic and life-threatening. We’re talking
about cardiovascular diseases, an in particular, pulmonary arterial
hypertension.

Guess what? The number of folks affected by those diseases is only going to go
up… and therefore the stock price.

The market cap is a whopping $12 billion. And you likely know the healthcare
sector has been on a bit of a rip this year.

Now I’ll tell you what I like about the company. Let’s hit the numbers.

Value-growth-income, my proprietary algorithm to measure companies for being
undervalued and having good income, good sales growth, and good profitability
growth, this is a 9. Anything 7, 8, 9 hits the mark. The forecast P/E ratio –
remember, it’s basically a technology company – is only 11.5. So you’re paying
$11.50 for every future dollar of profits.

Cash return on capital invested is 12%. Not bad, certainly for a company that
has to spend a lot on investment.

Why is that important? Click here to see how Goldman Sachs discovered that CROCI
is so critically important.

Again… cash return on capital invested, 12%. Fantastic.

The Sortino is not bad. That’s the average return versus the downside risk of
missing it. I want it to be above 0.3. That’s not bad.

Not a very volatile stock, which is good. It outperforms the market.



You can see the trend direction. You can see the price direction. You can see,
on an upward trend, the worst-case drawdown is about 16% over a two-month
period. That’s a drawdown that I think most people could stomach.



So it’s on the way up. I like it. I like the direction. I like what’s happening
with it. I love it all.

It’s 60% undervalued on a discount cash flow basis.



It’s Father’s Day. So I’m going to go with my son. I managed to get that done
just in time for you, but you didn’t miss anything.

Overall, it’s a solid company.

You can see that the analysts like it as well. Happy Father’s Day to all of you,
whichever part of the world you’re celebrating in.


NVIDIA'S SECRET PARTNER... THIS IS THE NEW AI CHIP POWERHOUSE

I bet you've never heard of it... but this newly public company is set to become
key to Nvidia's seat on the AI throne. And for now... you can get in while it's
still cheap.

Details here.

ALPESH PATEL

Alpesh Patel is an award-winning hedge fund and private equity fund manager,
international best-selling author, entrepreneur and Dealmaker. He is the Founder
and CEO of Praefinium Partners and is a Financial Times Top FTSE 100 forecaster.
As a senior-most Dealmaker in the U.K.’s Department for International Trade, he
is part of a team that has helped deliver $1 billion of investment to the U.K.
since 2005 . He’s also a former Council Member of the 100-year-old Chatham
House, the foreign affairs think-tank, whose patron is Queen Elizabeth. For his
services to the U.K. economy, Alpesh received the Order of the British Empire
(OBE) from the Queen in 2020. As a recognized authority on fintech, online
trading and venture capital, his past and current client list includes American
Express, Merrill Lynch HSBC, Charles Schwab, Goldman Sachs, Barclays, TD Bank,
NYSE Life… and more.

--------------------------------------------------------------------------------


MORE VIDEOS

DEALMAKER’S DIARY: ADD THIS UNDERVALUED RETAIL PIONEER TO YOUR CART

This bulk retail pioneer has been serving up jumbo-sized gains over the past few
years. Get the ticker here.

BUY THIS, NOT THAT: PUT THESE CONTROVERSIAL STOCKS ON YOUR “BUY” LIST

It doesn’t matter what they do or where they do it. Are they making money? These
five Chinese stocks are.

MONDAY TAKEAWAYS: THE MAGNIFICENT SEVEN’S CREATIVE DESTRUCTION

Barron’s is out with a piece that suggests it’s time to get out of the
Magnificent Seven. Here’s why that’s wrong.

BUY THIS, NOT THAT: SUMMER SIZZLERS AND VACATION BUSTS

As summer travel kicks into high gear, here are six travel and leisure stocks
that should be either added to your bucket list… or be given one-star reviews.

View Video Archive


SIGN UP TO RECEIVE THE BEST INVESTING TIPS AND TRICKS IN YOUR INBOX DAILY FROM
OUR FREE E-LETTER TOTAL WEALTH.



By submitting your email address, you will receive a free subscription to the
Total Wealth e-letter, and offers from us and our affiliates that we think might
interest you. You can unsubscribe at any time. Privacy Policy.

BROUGHT TO YOU BY MANWARD PRESS

 * Archive
 * Contact
 * Partner With Us
 * Privacy Policy
 * FAQ
 * Terms & Conditions
 * Disclaimer

 * Not Receiving Our Emails?
 * Do Not Sell or Share My Personal Information

VISIT MANWARD PRESS
FACEBOOK | YOUTUBE

©2024 Manward Press, LLC | All Rights Reserved | 14 West Mount Vernon Place,
Baltimore, MD 21201 USA
North America: 1.800.682.5210 | International: +1.443.353.4263